Ignite Creation Date:
2024-05-06 @ 1:58 AM
Last Modification Date:
2024-10-26 @ 11:12 AM
Study NCT ID:
NCT01945164
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2014-10-21
First Post:
2012-12-07
Brief Title:
XL999 Administered Intravenously to a Subject With Advanced Malignancies
Sponsor:
John Sarantopoulos
Organization:
The University of Texas Health Science Center at San Antonio
Study Overview
Official Title:
Single Patient Treatment Study for the Use of XL999 Administered Intravenously to a Subject With Advanced Malignancies Previously Enrolled in Study XL999-900
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cancer is a worldwide clinical and economic problem Conventional approaches to treating cancer include surgery radiotherapy and cytotoxic chemotherapy as single modalities or as combined therapies Recently targeted therapies including antibodies and small molecule inhibitors have also demonstrated clinical benefit It is now possible to study different genetic lesions involved in cancer types due to advances in genomic methodologies The investigational drug in this study XL999 inhibits multiple receptor tyrosine kinases including VEGF receptor VEGFR2KDR platelet derived growth factor receptors PDGFRβ fms-like tyrosine kinase receptor 3 FLT3 fibroblast growth factor receptors FGFR1 FGFR3 RET and KIT and thus interferes with multiple cellular processes simultaneously and will likely have effects on the integrity of tumor neovasculature and angiogenesis Together with the ability to induce a novel cell cycle arrest the spectrum of activities that XL999 exhibits may reduce both tumor cell proliferation and angiogenesis in the clinic
The rationale and purpose of this maintenance study is to allow a subject receiving clinical benefit from XL999 to continue treatment
The rationale and purpose of this maintenance study is to allow a subject receiving clinical benefit from XL999 to continue treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HSC20100312H | OTHER | UTHSCSA IRB | None |